as attached
ERIS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Eris Lifesciences reported audited consolidated results for FY2026 ending March 31. Total revenue from operations grew 8.1% to Rs 3,129.42 crore from Rs 2,893.64 crore. Net profit surged 72.8% to Rs 647.51 crore vs Rs 374.67 crore, driven partly by a deferred tax credit of Rs 150 crore from the new Income Tax Act 2025 concessional regime and Rs 17.24 crore exceptional item (increase in gratuity/leave liability from new labour codes). Operating margin expanded to 27.1% from 24.9% a year ago. The Board declared an interim dividend of Rs 7.21 per share (721% on Re. 1 face value). Auditors Walker Chandiok & Co LLP issued unmodified opinions on both standalone and consolidated financials with no qualifications. The company completed acquisition of Swiss Parenterals (now wholly-owned subsidiary) and the branded probiotics business from Velbiom for Rs 50 crore.
Strong bottom-line growth driven by tax benefits and margin expansion is positive for shareholders. The healthy dividend declaration reinforces investor confidence. However, the standalone entity showed a loss in Q4 due to higher costs, which warrants monitoring.